What’s behind Pharmaxis’ recent deal with Boehringer Ingleheim?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: What’s behind Pharmaxis’ recent deal with Boehringer Ingleheim?
Released on: December 15, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Gary Philips, CEO to Pharmaxis, reveals the reasons behind the company’s change in direction, leading up to one of the largest deals for a phase I asset in Australia.
  • Summary
  • Transcript
  • Participants
  • Company
Gary Philips, CEO to Pharmaxis, reveals the reasons behind the company’s change in direction, leading up to one of the largest deals for a phase I asset in Australia.
Gary Philips, CEO to Pharmaxis, reveals the reasons behind the company’s change in direction, leading up to one of the largest deals for a phase I asset in Australia.
Gary Phillips was appointed Chief Executive Officer and a member of the Pharmaxis Board of Directors in March 2013. Mr Phillips joined Pharmaxis in December 2003 when the company listed on the Australian Securities Exchange. He served as Commercial Director until June 2008 when he was appointed the company’s Chief Operating Officer. In this role he expanded Pharmaxis’ Commercial infrastructure in Europe and the USA, and worked closely with the clinical development, regulatory approval processes and reimbursement of Pharmaxis products Aridol and Bronchitol. Mr Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. From 1998 to 2003, Mr. Phillips held various positions within Novartis Asia Pacific, first as a Regional Manager responsible for the P&L of 8 countries and most recently as Chief Executive Officer of Novartis Pharmaceuticals Australia Pty Ltd, where he successfully launched leading oncology and ophthalmology products and relaunched newly acquired primary care products. From 1992 to 1998, Mr. Phillips served as Chief Executive Officer at Ciba Geigy in Hungary (Merged to form Novartis in 1996) where he led the launch of multiple new products and achieved the leading market share amongst multinational pharmaceutical companies. Gary Phillips holds a B. Pharm. in Pharmacy with honors from Nottingham University in the U.K. and an M.B.A. from Henly Management College.
Pharmaxis was founded more than ten years ago on an important Australian research discovery. Today, Pharmaxis is working to bring innovative medicines to millions of people worldwide, touching and improving their lives as it does so. Listed on the Australian Stock Exchange in 2003, Pharmaxis is a specialty pharmaceutical company involved in the research, development and commercialisation of new human healthcare products to treat and manage diseases with high unmet need.